Strategies for cardiovascular risk assessment and prevention over the life course: Progress amid imperfections

Circulation

Volumn 120, Issue 5, 2009, Pages 360-363

  Vasan, Ramachandran S ^a,b   Kannel, William B ^a,b  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Editorials; Epidemiology; Prevention; Risk factors

Indexed keywords

ALGORITHM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; EDITORIAL; EVIDENCE BASED PRACTICE; HIGH RISK POPULATION; HUMAN; LIFE EVENT; LIFESPAN; MORBIDITY; MORTALITY; PREDICTIVE VALIDITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

CARDIOVASCULAR DISEASES; HUMANS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 68249114280     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.881995     Document Type: Editorial

References (17)

1. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28:2375-2414.
2. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365:434-441.
3. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
4. Brenner H, Gefeller O, Greenland S. Risk and rate advancement periods as measures of exposure impact on the occurrence of chronic diseases. Epidemiology. 1993;4:229-236.
5. Cavanaugh-Hussey MW, Berry JD, Lloyd-Jones DM. Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool. Prev Med. 2008;47:619-623.
6. Marma AK, Lloyd-Jones DM. Systematic examination of the updated Framingham Heart Study general cardiovascular risk profile. Circulation. 2009;120:384-390.
7. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PWF, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791-798.
8. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF, Shea S, Sidney S, O'Leary DH, Chan C, Lloyd-Jones DM. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the Coronary Artery Risk Development in Young Adults Study and Multi-Ethnic Study of Atherosclerosis. Circulation. 2009;119:382-389.
9. Jackson R. Cardiovascular risk prediction: are we there yet? Heart. 2008;94:1-3.
10. Essink-Bot ML, Kruijshaar ME, Barendregt JJ, Bonneux LGA. Evidence-based guidelines, time-based health outcomes, and the Matthew effect. Eur J Public Health. 2007;17:314-317.
11. Bonneux L. Cardiovascular risk models. BMJ. 2007;335:107-108.
12. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-98.
13. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:3078-3084.
14. National Collaborating Centre for Primary Care. Cardiovascular Risk Assessment: The Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease: Full Guideline, Consultation Draft. London, UK: National Collaborating Centre for Primary Care; 2007.
15. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475-1482.
16. Woodward M, Brindle P, Tunstall-Pedoe H, for the SIGN Group on Risk Estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172-176.
17. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.